Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 5/20 | 0.50 |
| ▸ | CA6 | P23280 | 5/20 | 0.50 |
| ▸ | CA7 | P43166 | 5/20 | 0.50 |
| ▸ | CA9 | Q16790 | 5/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 5/20 | 0.50 |
| ▸ | CA5B | Q9Y2D0 | 5/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | RECQL | P46063 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 4/20 | 0.48 |
| ▸ | CA4 | P22748 | 4/20 | 0.48 |
| ▸ | CA5A | P35218 | 4/20 | 0.48 |
| ▸ | CA1 | P00915 | 4/20 | 0.48 |
| ▸ | CA3 | P07451 | 3/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | PAOX | Q6QHF9 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL9011763 | 0.98 | CA12 (0.48) | CA12CA6CA7CA9CA14 | |
| Acetic Acid SCHEMBL7517389 | 0.98 | CA12 (0.48) | CA12CA6CA7CA9CA14 | |
| Acetic Acid SCHEMBL1507469 | 0.97 | CA12 (0.53) | CA12CA6CA7CA9CA14 | |
| Acetic Acid SCHEMBL10939641 | 0.97 | CA12 (0.53) | CA12CA6CA7CA9CA14 | |
| Trientine SCHEMBL9794966 | 0.95 | CA12 (0.55) | CA12CA6CA7CA9CA14 | |
| Acetic Acid SCHEMBL15950216 | 0.95 | CA12 (0.50) | CA12CA6CA7CA9CA14 | |
| Acetic Acid SCHEMBL2092027 | 0.95 | CA12 (0.50) | CA12CA6CA7CA9CA14 | |
| Acetic Acid SCHEMBL9806060 | 0.95 | CA12 (0.56) | CA12CA6CA7CA9CA14 | |
| Acetic Acid SCHEMBL10929718 | 0.93 | CA12 (0.48) | CA12CA6CA7CA9CA14 | |
| Acetic Acid SCHEMBL11455369 | 0.92 | CA12 (0.53) | CA12CA6CA7CA9CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116997335-A | Preventive or therapeutic agent for side effects of anthracycline anticancer agent | 国立大学法人九州大学 | 2023-11-03 | — | — | CN | claimed |
| CN-109689038-B | Aqueous preparation containing 5-aminoacetopropionic acids | 思佰益药业股份有限公司 | 2022-05-13 | — | — | CN | claimed |
| CN-110028946-B | Solid acid rod for water injection well and preparation and injection method thereof | 中国石油天然气股份有限公司 | 2021-11-02 | — | — | CN | claimed |
| CN-106474098-B | Immune tolerance inducer | 思佰益药业股份有限公司 | 2020-06-05 | — | — | CN | claimed |
| CN-106661550-B | Agent for improving normal development rate of fertilized egg | 思佰益药业股份有限公司 | 2020-03-20 | — | — | CN | claimed |
| US-20170056351-A1 | COMPOSITION FOR INDUCING TUMOR IMMUNITY | UNIVERISTY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH, JAPAN (JP) | 2017-03-02 | — | — | US | claimed |
| US-12558333-B2 | Agent for ameliorating and/or preventing sickle cell disease | THE UNIVERSITY OF TOKYO (JP) | 2026-02-24 | — | — | US | disclosed |
| CN-116997335-A | Preventive or therapeutic agent for side effects of anthracycline anticancer agent | 国立大学法人九州大学 | 2023-11-03 | — | — | CN | disclosed |
| US-20220331276-A1 | AGENT FOR AMELIORATING AND/OR PREVENTING SICKLE CELL DISEASE | NEOPHARMA JAPAN CO., LTD. (JP) | 2022-10-20 | — | — | US | disclosed |
| CN-110339207-B | Prophylactic and/or therapeutic agent for side effects of anticancer agent | 思佰益药业股份有限公司 | 2022-08-05 | — | — | CN | disclosed |
| EP-4032587-A1 | AGENT FOR AMELIORATING AND/OR PREVENTING SICKLE CELL DISEASE | The University of Tokyo (JP) | 2022-07-27 | — | — | EP | disclosed |
| CN-113747946-A | Therapeutic agent for flavivirus infection | 日本纽翱医药股份有限公司 | 2021-12-03 | — | — | CN | disclosed |
| CN-110028946-B | Solid acid rod for water injection well and preparation and injection method thereof | 中国石油天然气股份有限公司 | 2021-11-02 | — | — | CN | disclosed |
| EP-0350923-B1 | A METHOD AND A SOLUTION FOR PROCESSING PHOTOSENSITIVE SILVER HALIDE COLOR PHOTOGRAPHIC MATERIALS | KONICA CORPORATION (JP) | 1993-09-15 | — | — | EP | disclosed |
| EP-0551757-A1 | Processing solution for silver halide colour photographic materials | KONICA CORPORATION (JP) | 1993-07-21 | — | — | EP | disclosed |
| EP-0219113-B1 | METHOD OF PROCESSING SILVER HALIDE COLOR PHOTOGRAPHIC MATERIAL | FUJI PHOTO FILM CO., LTD. (JP) | 1993-01-27 | — | — | EP | disclosed |
| US-4980272-A | Method and a solution for processing a photosensitive silver halide color photographic materials | KONICA CORPORATION (JP) | 1990-12-25 | — | — | US | disclosed |
| EP-0350923-A2 | A method and a solution for processing photosensitive silver halide color photographic materials | KONICA CORPORATION (JP) | 1990-01-17 | — | — | EP | disclosed |
| US-4769312-A | Method of processing silver halide color photographic material including the use of a two bath desilvering system comprising two baths | FUJI PHOTO FILM CO., LTD. (JP) | 1988-09-06 | — | — | US | disclosed |
| EP-0219113-A2 | Method of processing silver halide color photographic material | FUJI PHOTO FILM CO., LTD. (JP) | 1987-04-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12558333-B2 | Agent for ameliorating and/or preventing sickle cell disease | HBB, HBZ, HBG1 | CA12 947/4885CA6 829/4885CA7 1084/4885 |
| US-20170056351-A1 | COMPOSITION FOR INDUCING TUMOR IMMUNITY | IFNG, MYD88, IL2 | CA12 352/4885CA6 873/4885CA7 344/4885 |
| US-20220331276-A1 | AGENT FOR AMELIORATING AND/OR PREVENTING SICKLE CELL DISEASE | ALAD, SOD1, SLC30A5 | CA12 1001/4885CA6 470/4885CA7 1181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.